115 related articles for article (PubMed ID: 12837768)
1. chi-Conopeptide MrIA partially overlaps desipramine and cocaine binding sites on the human norepinephrine transporter.
Bryan-Lluka LJ; Bönisch H; Lewis RJ
J Biol Chem; 2003 Oct; 278(41):40324-9. PubMed ID: 12837768
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the norepinephrine transporter by the venom peptide chi-MrIA. Site of action, Na+ dependence, and structure-activity relationship.
Sharpe IA; Palant E; Schroeder CI; Kaye DM; Adams DJ; Alewood PF; Lewis RJ
J Biol Chem; 2003 Oct; 278(41):40317-23. PubMed ID: 12885787
[TBL] [Abstract][Full Text] [Related]
3. 'Messy' Processing of χ-conotoxin MrIA Generates Homologues with Reduced hNET Potency.
Ziegman R; Brust A; Jha P; Cardoso FC; Lewis RJ; Alewood PF
Mar Drugs; 2019 Mar; 17(3):. PubMed ID: 30875751
[TBL] [Abstract][Full Text] [Related]
4. The role of the conserved GXXXRXG motif in the expression and function of the human norepinephrine transporter.
Sucic S; Bryan-Lluka LJ
Brain Res Mol Brain Res; 2002 Dec; 108(1-2):40-50. PubMed ID: 12480177
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine residue 271 of the norepinephrine transporter is an important determinant of its pharmacology.
Paczkowski FA; Bryan-Lluka LJ
Brain Res Mol Brain Res; 2001 Dec; 97(1):32-42. PubMed ID: 11744160
[TBL] [Abstract][Full Text] [Related]
6. Solution structure of chi-conopeptide MrIA, a modulator of the human norepinephrine transporter.
Nilsson KP; Lovelace ES; Caesar CE; Tynngård N; Alewood PF; Johansson HM; Sharpe IA; Lewis RJ; Daly NL; Craik DJ
Biopolymers; 2005; 80(6):815-23. PubMed ID: 15931669
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological properties of the naturally occurring Ala(457)Pro variant of the human norepinephrine transporter.
Paczkowski FA; Bönisch H; Bryan-Lluka LJ
Pharmacogenetics; 2002 Mar; 12(2):165-73. PubMed ID: 11875370
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the norepinephrine transporter by χ-conotoxin dendrimers.
Wan J; Brust A; Bhola RF; Jha P; Mobli M; Lewis RJ; Christie MJ; Alewood PF
J Pept Sci; 2016 May; 22(5):280-9. PubMed ID: 26910400
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of drug interactions with recombinant biogenic amine transporters expressed in the same cell type.
Eshleman AJ; Carmolli M; Cumbay M; Martens CR; Neve KA; Janowsky A
J Pharmacol Exp Ther; 1999 May; 289(2):877-85. PubMed ID: 10215666
[TBL] [Abstract][Full Text] [Related]
10. chi-Conotoxin and tricyclic antidepressant interactions at the norepinephrine transporter define a new transporter model.
Paczkowski FA; Sharpe IA; Dutertre S; Lewis RJ
J Biol Chem; 2007 Jun; 282(24):17837-44. PubMed ID: 17428804
[TBL] [Abstract][Full Text] [Related]
11. Amino acids involved in differences in the pharmacological profiles of the rat and human noradrenaline transporters.
Paczkowski FA; Bryan-Lluka LJ
Naunyn Schmiedebergs Arch Pharmacol; 2002 Apr; 365(4):312-7. PubMed ID: 11919656
[TBL] [Abstract][Full Text] [Related]
12. Determination of residues in the norepinephrine transporter that are critical for tricyclic antidepressant affinity.
Roubert C; Cox PJ; Bruss M; Hamon M; Bönisch H; Giros B
J Biol Chem; 2001 Mar; 276(11):8254-60. PubMed ID: 11092898
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological properties of naturally occurring variants of the human norepinephrine transporter.
Runkel F; Brüss M; Nöthen MM; Stöber G; Propping P; Bönisch H
Pharmacogenetics; 2000 Jul; 10(5):397-405. PubMed ID: 10898109
[TBL] [Abstract][Full Text] [Related]
14. Investigation of the functional roles of the MELAL and GQXXRXG motifs of the human noradrenaline transporter using cysteine mutants.
Sucic S; Bryan-Lluka LJ
Eur J Pharmacol; 2007 Feb; 556(1-3):27-35. PubMed ID: 17141753
[TBL] [Abstract][Full Text] [Related]
15. Delineation of an endogenous zinc-binding site in the human dopamine transporter.
Norregaard L; Frederiksen D; Nielsen EO; Gether U
EMBO J; 1998 Aug; 17(15):4266-73. PubMed ID: 9687495
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of transport function and desipramine binding at the human noradrenaline transporter by N-ethylmaleimide and protection by substrate analogs.
Foley KF; Cozzi NV
Naunyn Schmiedebergs Arch Pharmacol; 2002 Jun; 365(6):457-61. PubMed ID: 12070759
[TBL] [Abstract][Full Text] [Related]
17. Inability to N-glycosylate the human norepinephrine transporter reduces protein stability, surface trafficking, and transport activity but not ligand recognition.
Melikian HE; Ramamoorthy S; Tate CG; Blakely RD
Mol Pharmacol; 1996 Aug; 50(2):266-76. PubMed ID: 8700133
[TBL] [Abstract][Full Text] [Related]
18. Roles of transmembrane domain 2 and the first intracellular loop in human noradrenaline transporter function: pharmacological and SCAM analysis.
Sucic S; Bryan-Lluka LJ
J Neurochem; 2005 Sep; 94(6):1620-30. PubMed ID: 16092934
[TBL] [Abstract][Full Text] [Related]
19. Identification of a single amino acid, phenylalanine 586, that is responsible for high affinity interactions of tricyclic antidepressants with the human serotonin transporter.
Barker EL; Blakely RD
Mol Pharmacol; 1996 Oct; 50(4):957-65. PubMed ID: 8863842
[TBL] [Abstract][Full Text] [Related]
20. Determinants within the C-terminus of the human norepinephrine transporter dictate transporter trafficking, stability, and activity.
Bauman PA; Blakely RD
Arch Biochem Biophys; 2002 Aug; 404(1):80-91. PubMed ID: 12127072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
